Condition

Metastatic Castration-resistant Prostate Cancer clinical trials and research

• 65Clinical trials
• 39Countries

Newest Metastatic Castration-resistant Prostate Cancer clinical trials

All recruiting trials (65)

• JUR-003 in adults with advanced prostate cancer

  This first-in-human study tests JUR-003 to see if it is safe and tolerable and to get an early sense of activity in adults with metastatic or advanced prostate cancer.

  Recruiting at 4 sites Phase 1 TCG Labs Soleil · Grand Rapids, Michigan and 3 other locations · NCT07824349

• SRT-017 radioligand therapy in PSMA-positive metastatic castration-resistant prostate cancer

  This study tests SRT-017 given by IV infusion to men with PSMA-positive metastatic castration-resistant prostate cancer to see if it is safe and tolerable and to gather early signals of anti-tumor activity.

  Recruiting Early Phase 1 Affiliated Hospital of Jiangnan University · Wuxi, Jiangsu · NCT07798778

• Rinzimetostat plus darolutamide in metastatic castration-resistant prostate cancer after abiraterone failure

  This study tests whether adding rinzimetostat to darolutamide helps people with metastatic castration-resistant prostate cancer who previously took abiraterone.

  Recruiting at 15 sites Phase 3 ORIC Pharmaceuticals · Glendale, California and 14 other locations · NCT07723248

• FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer

  This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.

  Recruiting at 7 sites Phase 1 Flare Therapeutics Inc. · Los Angeles, California and 9 other locations · NCT07719361

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Dual-target PSMA/PSCA CAR-NK Therapy in Advanced Prostate Cancer

  This trial tests ETB-DualNK-01, a dual-target CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer to see if it is safe and shows early signs of activity.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07641049

• AZD2265 plus standard care vs standard care in PSMA-positive metastatic castration-resistant prostate cancer

  Aims to see if AZD2265 can extend radiographic progression-free survival and overall survival compared with standard treatments for men with PSMA-positive metastatic castration-resistant prostate cancer.

  Recruiting at 19 sites Phase 3 AstraZeneca · Dothan, Alabama and 150 other locations · NCT07611110

• Is CSE-MRI as good as FLT PET for spotting active bone marrow in men with advanced prostate cancer

  This study tests whether a special MRI method can match FLT PET in telling active bone marrow from inactive bone marrow in men with metastatic, treatment‑resistant prostate cancer who are receiving Lu-177 PSMA therapy.

  Recruiting Early Phase 1 University of Wisconsin, Madison · Madison, Wisconsin · NCT07609225

• JANX014 for metastatic castration-resistant prostate cancer

  This trial will test whether JANX014 is safe, how your body handles it, and whether it shows signs of benefit in adults with metastatic castration-resistant prostate cancer who have already had anti-androgen therapy and typically a taxane.

  Recruiting at 6 sites Phase 1 Janux Therapeutics · La Jolla, California and 5 other locations · NCT07545811

• High-dose testosterone followed by PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer

  This trial tests whether short-term high-dose testosterone followed by a PSMA-targeted radioligand (PSMA-617) can help men with metastatic castration-resistant prostate cancer that is progressing on castrate-level testosterone.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07476001

• ITC-6146RO in advanced cancers beyond standard therapy

  A new drug called ITC-6146RO is being tested to see if it is safe and can help people with advanced cancers who have no other approved options.

  Recruiting at 3 sites Phase 1 IntoCell, Inc · Seoul, Seoul and 2 other locations · NCT07423117

• Actinium (225Ac) PSMA therapy for castration‑resistant prostate cancer after Lutetium

  This trial will test whether an injectable Actinium-225 PSMA treatment can control advanced prostate cancer in men whose disease progressed after Lutetium‑PSMA therapy.

  Recruiting Phase 1/2 University College, London · London · NCT07414940

• BNT324 versus docetaxel for metastatic castration-resistant prostate cancer

  This trial will test whether BNT324, an antibody‑drug conjugate immunotherapy, works better than standard chemotherapy (docetaxel plus prednisone or prednisolone) for men with metastatic castration‑resistant prostate cancer who have had prior androgen‑receptor pathway inhibitors but no prior taxane chemotherapy for mCR

  Recruiting at 52 sites Phase 3 BioNTech SE · Santa Barbara, California and 51 other locations · NCT07365995

• A-CAR032 CAR-T therapy for metastatic castration-resistant prostate cancer

  This early-phase treatment will try A-CAR032, a CAR-T cell therapy, in adults with metastatic castration‑resistant prostate cancer who progressed after ARPI and are not eligible for standard treatment.

  Recruiting at 2 sites Phase 1 Shanghai AbelZeta Ltd. · Beijing, Beijing Municipality and 3 other locations · NCT07344311

• ASP5541 with prednisone and ADT for Chinese men with prostate cancer

  This study tests whether giving ASP5541 together with prednisone and ongoing androgen-deprivation therapy is safe and how the medicine behaves in Chinese men with metastatic prostate cancer.

  Recruiting Phase 1 Astellas Pharma Inc · Beijing, Beijing Municipality · NCT07339267

• GVV858 alone or with fulvestrant or letrozole for HR+/HER2- breast cancer and other advanced tumors

  This trial tests whether GVV858 alone or with fulvestrant or letrozole can help adults with HR+/HER2- advanced breast cancer, CCNE1‑amplified solid tumors, or metastatic castration‑resistant prostate cancer.

  Recruiting at 16 sites Phase 1/2 Novartis · Atlanta, Georgia and 15 other locations · NCT07288359

• Inavolisib plus enzalutamide for metastatic castration-resistant prostate cancer

  This phase 2 trial will test whether adding inavolisib to enzalutamide helps biomarker-selected patients with metastatic castration-resistant prostate cancer who have already received one second-generation androgen-receptor pathway inhibitor.

  Recruiting at 50 sites Phase 2 Hoffmann-La Roche · Los Angeles, California and 49 other locations · NCT07287150

• Valemetostat plus darolutamide for metastatic castration‑resistant prostate cancer

  This trial tests whether combining valemetostat with darolutamide is safe and tolerable for men whose prostate cancer has spread and no longer responds to hormone therapy.

  Recruiting at 29 sites Phase 1 Daiichi Sankyo · La Jolla, California and 28 other locations · NCT07244341

• Xaluritamig plus abiraterone versus doctor's choice for chemo‑naïve metastatic castration‑resistant prostate cancer

  This phase 3 test checks whether adding xaluritamig to abiraterone helps men with chemotherapy‑naïve metastatic castration‑resistant prostate cancer live longer than standard doctor‑chosen options (docetaxel, cabazitaxel, or abiraterone alone).

  Recruiting at 154 sites Phase 3 Amgen · Goodyear, Arizona and 158 other locations · NCT07213674

• DS9051b for advanced or metastatic adrenocortical carcinoma and metastatic castration‑resistant prostate cancer

  This trial will try an experimental drug called DS9051b in adults with advanced adrenocortical carcinoma or metastatic castration‑resistant prostate cancer to see if it is safe and shows early signs of benefit.

  Recruiting at 4 sites Phase 1 Daiichi Sankyo · Sarasota, Florida and 5 other locations · NCT07189403

• Alternating high-dose testosterone with darolutamide to extend hormone response in metastatic prostate cancer

  This trial will test whether alternating high-dose testosterone with the antiandrogen darolutamide can prolong hormone control and improve quality of life for men with metastatic castration-resistant prostate cancer.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07142551

• KTX-2001 (alone and with darolutamide) for men with metastatic castration‑resistant prostate cancer

  This trial tests whether KTX-2001, by itself and combined with darolutamide, can help men whose prostate cancer has spread and stopped responding to hormone therapies.

  Recruiting at 13 sites Phase 1 K36 Therapeutics, Inc. · San Francisco, California and 12 other locations · NCT07103018

• Phase 2 test of ASP5541 for men with advanced prostate cancer

  This study will test whether an injectable form of abiraterone (ASP5541) is safe and works as well or better than the standard oral abiraterone for men with metastatic prostate cancer who are on hormone therapy, with or without prednisone.

  Recruiting at 54 sites Phase 2 Astellas Pharma Inc · Huntsville, Alabama and 53 other locations · NCT07005154

• Treatment for advanced prostate cancer using Pluvicto

  This study is testing if a new treatment called Pluvicto can help men with advanced prostate cancer that has spread to their bones feel better and improve their quality of life.

  Recruiting Phase 2 Excel Diagnostics and Nuclear Oncology Center · Houston, Texas · NCT06972628

• Combining radiotherapy with fluzopanib and abiraterone for advanced prostate cancer

  This study is testing whether combining radiation therapy with two medications, fluzopanib and abiraterone, can help men with advanced prostate cancer feel better and live longer.

  Recruiting Phase 2 First Hospital of China Medical University · Shenyang, Liaoning · NCT06971211

• Combining high-dose testosterone with ZEN-3694, then enzalutamide plus ZEN-3694 for resistant prostate cancer

  This trial will test whether cycles of high-dose testosterone together with ZEN-3694, followed by enzalutamide plus ZEN-3694, can shrink tumors or delay progression in men with metastatic castration‑resistant prostate cancer who have progressed on prior AR-directed therapy.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06922318

• Evaluating a new treatment for advanced prostate cancer

  This study is testing a new combination of drugs to see if they are safe and effective for people with advanced prostate cancer that hasn’t responded to other treatments.

  Recruiting at 7 sites Phase 1 AstraZeneca · Palo Alto, California and 15 other locations · NCT06879041

• Re-treatment with a targeted radiotherapy for men with advanced prostate cancer

  This study is testing if giving a targeted radiotherapy again can help men with advanced prostate cancer who previously responded to the treatment feel better and live longer.

  Recruiting Phase 2 Hospices Civils de Lyon · Bordeaux and 15 other locations · NCT06866938

• FG-3246 for metastatic castration-resistant prostate cancer

  This trial tests FG-3246, a CD46-targeting antibody-drug conjugate, in men with metastatic castration-resistant prostate cancer who progressed after one second-generation hormone therapy and have not received taxane chemotherapy for their metastatic disease.

  Recruiting at 23 sites Phase 2 Kyntra Bio · Goodyear, Arizona and 22 other locations · NCT06842498

• Registry for prostate cancer treatment and outcomes

  This study is tracking the treatment and progress of men with recurrent and advanced prostate cancer to see how different therapies affect their lives over time.

  Recruiting at 53 sites UroTrials Company (GmbH) · Freiburg im Breisgau, Baden-Wurttemberg and 52 other locations · NCT06835218

• Cabazitaxel (with or without carboplatin) versus 177Lu-PSMA-617 for PSMA-positive metastatic castration-resistant prostate cancer

  This trial will try whether cabazitaxel (with or without carboplatin) or the PSMA-targeted radioligand 177Lu-PSMA-617 works better for people with PSMA-positive metastatic castration-resistant prostate cancer who have progressed after hormonal therapy.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06738303

• Investigating PF-06821497 for men with advanced prostate cancer

  This study is testing if a new drug called PF-06821497 can help men with advanced prostate cancer feel better when used with a standard treatment compared to a placebo.

  Recruiting at 203 sites Phase 3 Pfizer · Chandler, Arizona and 230 other locations · NCT06629779

• Treatment of metastatic castration-resistant prostate cancer with XL092

  This study is testing if the oral drug XL092 can help people with advanced prostate cancer that hasn’t responded to other treatments.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT06568562

• Evaluating SYNC-T Therapy SV-102 for advanced prostate cancer

  This study is testing a new treatment called SYNC-T Therapy SV-102 to see if it can help men with advanced prostate cancer who haven't had success with other therapies.

  Recruiting at 14 sites Phase 2 Syncromune, Inc. · Phoenix, Arizona and 22 other locations · NCT06533644

• Using organoid testing to guide treatment for advanced prostate cancer

  This study is testing if using lab-grown mini tumors from prostate cancer patients can help doctors choose better treatments for men with advanced prostate cancer that hasn't responded to initial therapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT06529549

• Evaluating 177Lu-TLX591 with standard care for advanced prostate cancer

  This study is testing if adding a new treatment called 177Lu-TLX591 to standard care can help men with advanced prostate cancer who haven't responded to other treatments live longer without their cancer getting worse.

  Recruiting at 22 sites Phase 3 Telix Pharmaceuticals (Innovations) Pty Limited · Orange, California and 32 other locations · NCT06520345

• Evaluating the use of lutetium vipivotide tetraxetan in advanced prostate cancer

  This study is trying to see how the treatment lutetium vipivotide tetraxetan affects the quality of life for men with advanced prostate cancer over the course of their treatment and follow-up.

  Recruiting at 38 sites Novartis · Konstanz, Baden-Wurttemberg and 37 other locations · NCT06517719

• Pluvicto post-marketing safety and effectiveness in Korea.

  This program will follow men in Korea with metastatic castration-resistant prostate cancer who are receiving Pluvicto to see if the treatment is safe and works in routine care.

  Recruiting at 12 sites Novartis · Seongnam-si, Gyeonggi-do and 11 other locations · NCT06514521

• Evaluating a new treatment for advanced prostate cancer

  This study is testing a new drug for advanced prostate cancer to see if it's safe and how well it works for patients whose cancer has spread and is resistant to other treatments.

  Recruiting at 11 sites Phase 1 Full-Life Technologies UK Limited · Duarte, California and 10 other locations · NCT06492122

• Using ebastine with docetaxel to treat advanced prostate cancer

  This study is testing whether adding ebastine to the standard prostate cancer treatment with docetaxel can help men with advanced prostate cancer feel better and improve their health.

  Recruiting Phase 1/2 Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT06480110

• Combining carboplatin with docetaxel for advanced prostate cancer treatment

  This study is testing if adding carboplatin to the usual treatment of docetaxel can help people with advanced prostate cancer by slowing down the growth or spread of their disease.

  Recruiting at 14 sites Phase 3 Canadian Cancer Trials Group · Calgary, Alberta and 13 other locations · NCT06439225

• Using darolutamide for advanced prostate cancer treatment

  This study is testing if darolutamide can help men with advanced prostate cancer who have already been treated feel better and live longer without their cancer getting worse.

  Recruiting at 12 sites Phase 2 Swiss Cancer Institute · Aarau and 12 other locations · NCT06401980

• Akkermansia muciniphila in the gut of men with advanced prostate cancer

  This research will test whether levels of the gut bacterium Akkermansia muciniphila are linked to treatment response in men with metastatic castration‑resistant prostate cancer who are starting abiraterone or similar hormone therapy.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT06242509

• Combining SX-682 with enzalutamide for men with advanced prostate cancer resistant to abiraterone

  This study is testing whether combining SX-682 with enzalutamide can help men with advanced prostate cancer that hasn't improved with abiraterone.

  Recruiting at 5 sites Phase 2 Syntrix Biosystems, Inc. · Los Angeles, California and 5 other locations · NCT06228053

• Using modified T cells to target prostate cancer cells

  This study is testing a new treatment using modified T cells to see if it can help men with advanced prostate cancer who have run out of other options.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06193486

• Evaluating a new oral medication for advanced prostate cancer

  This study is testing a new oral medication for advanced prostate cancer to see if it is safe and effective for patients whose cancer has spread and is resistant to other treatments.

  Recruiting at 26 sites Phase 1/2 Hinova Pharmaceuticals Inc. · Hefei, Anhui and 26 other locations · NCT06155084

• Combining Sipuleucel-T with Bipolar Androgen Therapy for Advanced Prostate Cancer

  This study is testing if combining a new treatment with testosterone injections and Sipuleucel-T can boost the immune response and help men with advanced prostate cancer feel better.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT06100705

• Using a new imaging test for prostate cancer before treatment

  This study is testing a new imaging scan to see how well it can show the spread of advanced prostate cancer before starting treatment.

  Recruiting at 2 sites Phase 4 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT06099093

• Assessing BMS-986460 for advanced prostate cancer

  This study is testing a new treatment called BMS-986460 to see if it can help men with advanced prostate cancer who haven't responded to other therapies.

  Recruiting at 10 sites Phase 1 Bristol-Myers Squibb · Palo Alto, California and 14 other locations · NCT06067841

• FOG-001 treatment for advanced or metastatic solid tumors

  This study is testing a new drug called FOG-001 to see if it can help people with advanced solid tumors, especially those with certain genetic changes, when traditional treatments aren't working.

  Recruiting at 32 sites Phase 1/2 Parabilis Medicines, Inc. · Phoenix, Arizona and 32 other locations · NCT05919264

• Using a radiotracer to detect granzyme B in advanced cancers

  This study is testing a new imaging tool to see if it can help find specific markers in advanced cancers, especially in patients with kidney and prostate cancer, to better understand how their tumors respond to treatment.

  Recruiting Phase 1/2 University of California, San Francisco · San Francisco, California · NCT05888532

• Combining pembrolizumab with targeted radionuclide therapy for advanced prostate cancer

  This study is testing if combining pembrolizumab with a targeted radiation treatment can help men with advanced prostate cancer live longer and feel better after other treatments have stopped working.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT05766371

• Combining Docetaxel or Cabazitaxel with Darolutamide for Advanced Prostate Cancer

  This study is testing if adding darolutamide to chemotherapy drugs docetaxel or cabazitaxel can help men with advanced prostate cancer feel better and improve their treatment results.

  Recruiting Phase 2 Erasmus Medical Center · Rotterdam · NCT05762536

• Investigating a new treatment for advanced prostate cancer

  This study is testing a new treatment for advanced prostate cancer to see if it is safe and how well it works for patients whose cancer has spread and is resistant to other therapies.

  Recruiting at 3 sites Phase 1/2 AdvanCell Pty Limited · Brisbane, Queensland and 2 other locations · NCT05720130

• Combining cabozantinib with Lutetium-177 for advanced prostate cancer treatment

  This study is testing if combining cabozantinib with Lutetium-177 can safely help people with advanced prostate cancer.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT05613894

• 177Lu‑P17‑087 and 177Lu‑P17‑088 treatment for metastatic castration‑resistant prostate cancer

  This trial will test two new PSMA‑targeted radioactive drugs, 177Lu‑P17‑087 and 177Lu‑P17‑088, in men with metastatic castration‑resistant prostate cancer who have PSMA‑positive scans.

  Recruiting Early Phase 1 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT05603559

• Evaluating a new treatment for men with advanced prostate cancer

  This study is testing a new treatment for men with advanced prostate cancer to see if it's safe and how well it works after they've tried other therapies.

  Recruiting Phase 1/2 Peter MacCallum Cancer Centre, Australia · Melbourne, Victoria · NCT05521412

• Testing JANX007 for advanced prostate cancer

  This study is testing a new treatment called JANX007 combined with Darolutamide to see if it helps adults with advanced prostate cancer who haven't responded to other therapies.

  Recruiting at 38 sites Phase 1 Janux Therapeutics · Birmingham, Alabama and 37 other locations · NCT05519449

• Evaluating Datopotamab Deruxtecan for Advanced Solid Tumours

  This study is testing a new cancer treatment called Datopotamab Deruxtecan to see how well it works and how safe it is for people with advanced solid tumors like ovarian and colorectal cancers.

  Recruiting at 56 sites Phase 2 AstraZeneca · Los Angeles, California and 95 other locations · NCT05489211

• Treatment for advanced prostate cancer using Lutetium-177

  This study is testing a new treatment using Lutetium-177 for men with advanced prostate cancer that hasn't responded to other therapies to see how safe it is and how well it works.

  Recruiting at 20 sites Phase 1/2 Blue Earth Therapeutics Ltd · Miami, Florida and 20 other locations · NCT05413850

• Investigating the safety and effectiveness of REGN4336 for advanced prostate cancer

  This study is testing a new drug called REGN4336, alone and with other treatments, to see if it can safely help adults with advanced prostate cancer shrink their tumors.

  Recruiting at 13 sites Phase 1/2 Regeneron Pharmaceuticals · Palo Alto, California and 13 other locations · NCT05125016

• Using abemaciclib before a radioactive treatment for advanced prostate cancer

  This study is testing if taking abemaciclib before a radioactive treatment can help men with advanced prostate cancer feel better and improve their treatment results.

  Recruiting Phase 1/2 University of California, San Francisco · San Francisco, California · NCT05113537

• Combination of ZEN003694 and Enzalutamide for Advanced Prostate Cancer

  This study is testing if combining a new drug called ZEN003694 with enzalutamide can help men with advanced prostate cancer who didn't do well on previous treatments feel better compared to just using enzalutamide alone.

  Recruiting at 28 sites Phase 2 Zenith Epigenetics · Los Angeles, California and 30 other locations · NCT04986423

• Testing a new injection for men with advanced prostate cancer

  This study is testing a new injection for men with advanced prostate cancer to see how well it works and how safe it is.

  Recruiting at 15 sites Phase 1 Astellas Pharma Inc · Tucson, Arizona and 24 other locations · NCT04729114

• Tulmimetostat treatment for advanced solid tumors and lymphomas

  This study is testing a new treatment called Tulmimetostat to see if it can help people with advanced solid tumors and lymphomas feel better and fight their cancer.

  Recruiting at 43 sites Phase 1/2 Novartis · Tampa, Florida and 79 other locations · NCT04104776

Related topics

Quick answers

How many Metastatic Castration-resistant Prostate Cancer clinical trials are recruiting right now?

65, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 39 countries. The most sites are in United States (44 trials), China (16 trials), France (13 trials), Australia (12 trials), United Kingdom (12 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 19, Phase 1: 17, Phase 1/2: 13, Phase 3: 7. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →